Back to top
more

Cronos Group (CRON)

(Real Time Quote from BATS)

$2.42 USD

2.42
128,013

+0.04 (1.68%)

Updated Jul 12, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Ulta Beauty and Freshpet have been highlighted as Zacks Bull and Bear of the Day

Ulta Beauty and Freshpet have been highlighted as Zacks Bull and Bear of the Day

Tirthankar Chakraborty headshot

Ride The Cannabis Legalization Wave With These 3 Stocks

Stocks like Cronos Group (CRON), Canopy Growth (CGC) and Innovative Industrial Properties (IIPR) are sure to benefit at present amid the cannabis legalization wave.

Analysts Estimate Cronos Group (CRON) to Report a Decline in Earnings: What to Look Out for

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cronos Group (CRON) Reports Q2 Loss, Lags Revenue Estimates

Cronos (CRON) delivered earnings and revenue surprises of -28.57% and -13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for August 4th

ARRY, CRON, ESTC, LEVL and TME have been added to the Zacks Rank #5 (Strong Sell) List on August 4, 2021.

Will Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Madeleine Johnson headshot

Why Cannabis Giant Tilray (TLRY) Skyrocketed Today

Shares of Tilray (TLRY) closed sharply higher in Wednesday's trading session, gaining 25.8% after reporting mixed fourth-quarter earnings results.

New Strong Sell Stocks for July 16th

JAZZ, MRNS, TWO, NCMI, and CRON have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2021

Mark Vickery headshot

Markets Close Flat, Await New Jobs Data

Tomorrow brings us our first steady diet of useful economic data of the week, with both normal Thursday Initial Jobless Claims and ADP (ADP) private-sector payrolls.

Cronos (CRON) Moves 15.2% Higher: Will This Strength Last?

Cronos (CRON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Cronos Group (CRON) Reports Q1 Loss, Misses Revenue Estimates

Cronos (CRON) delivered earnings and revenue surprises of -50.00% and -25.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug/Biotech Stock Q1 Earnings on May 7: RDUS, CRON & OCGN

Let us take a look at three small biotech companies, RDUS, CRON and OCGN, which are gearing up for their earnings release.

New Strong Sell Stocks for May 3rd

BIDU, CRON, FORM, LTC, and SUNW have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2021

Earnings Preview: Cronos Group (CRON) Q1 Earnings Expected to Decline

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Mar 1, 2021

Companies in The News Are: CRON,PEG,SSP,BLDR

Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates

Cronos (CRON) delivered earnings and revenue surprises of -216.67% and 23.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Cronos (CRON) to Report Q4 Earnings: What's in the Offing?

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q4 results.

Sweta Killa headshot

Cannabis ETFs Spike on Jazz-GW Pharma Deal

Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.

The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ

The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ

Nitish Marwah headshot

4 Stocks to Ride the Wave of Cannabis Legalization

Increasing tolerance, financial protection, credit availability, and legal votes have shaped America's hemp industry lately.

Nitish Marwah headshot

4 Stocks to Ride the Wave of Cannabis Legalization

Increasing tolerance, financial protection, credit availability, and legal votes have shaped America's hemp industry lately.

Neena Mishra headshot

Should You Buy Cannabis Stocks & ETFs Now?

CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.

Cronos Group (CRON) Reports Q3 Loss, Tops Revenue Estimates

Cronos (CRON) delivered earnings and revenue surprises of 33.33% and 4.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Neena Mishra headshot

Why Cannabis Stocks & ETFs Are Soaring

Marijuana stocks are rising on hopes of favorable regulatory environment

Analysts Estimate Cronos Group (CRON) to Report a Decline in Earnings: What to Look Out for

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.